|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Herein, a theranostic strategy was carried to encapsulate a natural medicine (Quercetin, QR) into hepatitis B core (HBc) protein nanocages (NCs) for imaging and targeted treatment of hepatic fibrosis.
|
31644261 |
2019 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals.
|
29183719 |
2018 |
|
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In vitro assays with HBx, hepatitis B surface (HBs), or hepatitis B core (HBc) protein expression in HepG2 cells costimulated with ethanol were conducted to assess the cholesterol metabolism.
|
29133292 |
2018 |
|
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HBV-miR-3 targets the unique site of the HBV 3.5-kb transcript to specifically reduce HBc protein expression, levels of pregenomic RNA (pgRNA), and HBV replication intermediate (HBV-RI) generation but does not affect the HBV DNA polymerase level, thus suppressing HBV virion production (replication).
|
28148795 |
2017 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prevalence of HBV infection (current or past [presence of anti-HBc marker]) was 15.4% (95% CI: 8.7-25.8) and the rate of HBsAg carriers was 0.6% (95% CI: 0.2-1.6).
|
27508385 |
2016 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
We successfully inserted the 2β2-2β3 loop of PA into the major immunodominant region (MIR) of hepatitis B virus core (HBc) protein.
|
24054942 |
2014 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Capsid-like particles consisting of a hepatitis B core (HBc) protein have been studied for their potential as carriers for drug delivery systems (DDS).
|
23235317 |
2013 |
|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Involvement and consequences of the proteasomal degradation machinery in the HBc protein turnover during HBV infection with complex HBV variants in the immunosuppressed patients are discussed.
|
17607782 |
2007 |
|
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previous studies in rodent malaria models have shown that CS repeat B-cell epitopes expressed in a recombinant hepatitis B virus core (HBc) protein can elicit protective immunity.
|
12438363 |
2002 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Viral markers were used, including HBV DNA quantified by the branched DNA assay and detected by PCR, the HBV genome sequence, pre-S1Ag and anti-HBC IgM which were studied throughout the treatment period and the entire follow-up in the serum, while the presence of virus in extrahepatic sites was detected by immuno-staining.
|
11434628 |
2001 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have identified the presence of a nucleotide sequence at the start of the HBc gene in the hepatitis B virus genome similar to a consensus sequence known to occur upstream from genes induced by IFN in mammalian cells.
|
3517227 |
1986 |
|
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The temporal relation between the cytopathologic response and HBc gene expression was similar for both cell types, indicating a primary role for HBc gene expression in the cytopathology of HBV-infected human liver.
|
6194563 |
1983 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
Here, we aimed to identify Golgi-disrupting compounds from a panel of 34 approved anticancer drugs by using HBC-4 human breast cancer cells and immunofluorescence microscopy to visualize the Golgi apparatus.
|
30787205 |
2019 |
|
Malignant neoplasm of breast
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
We studied 1,018 women with a strong family history for breast cancer (families with hereditary breast cancer; HBC) from genetically homogenous population of Poland, which is populated by ethnic Slavs, for mutations in 14 cancer susceptibility genes.
|
31173646 |
2019 |
|
Breast Carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
We studied 1,018 women with a strong family history for breast cancer (families with hereditary breast cancer; HBC) from genetically homogenous population of Poland, which is populated by ethnic Slavs, for mutations in 14 cancer susceptibility genes.
|
31173646 |
2019 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Here, we aimed to identify Golgi-disrupting compounds from a panel of 34 approved anticancer drugs by using HBC-4 human breast cancer cells and immunofluorescence microscopy to visualize the Golgi apparatus.
|
30787205 |
2019 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
HBC-Evo: predicting human breast cancer by exploiting amino acid sequence-based feature spaces and evolutionary ensemble system.
|
25488423 |
2015 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
HBC-Evo: predicting human breast cancer by exploiting amino acid sequence-based feature spaces and evolutionary ensemble system.
|
25488423 |
2015 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
In spite of the recent demonstration and chromosomal localization of BC predisposing genes, clinical clues and careful inspection of pedigree still remain major instruments in HBC diagnosis.
|
10517166 |
1999 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
In spite of the recent demonstration and chromosomal localization of BC predisposing genes, clinical clues and careful inspection of pedigree still remain major instruments in HBC diagnosis.
|
10517166 |
1999 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
Two hypermethylation-containing fragments, HBC-1 (for "hypermethylation in breast cancer") and HBC-2, were identified in the amplified breast tumor DNA relative to the amplified normal breast DNA of a patient.
|
9067264 |
1997 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Further analysis showed that HBC-1 was methylated aberrantly in 90% (17 of 19 patients) of the primary breast carcinomas examined.
|
9067264 |
1997 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
HBC is common, accounting for approximately 9% of the total breast cancer burden.
|
2692910 |
1989 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
HBC is common, accounting for approximately 9% of the total breast cancer burden.
|
2692910 |
1989 |
|
Hereditary Breast and Ovarian Cancer Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Specific germline mutations in the hereditary breast-ovarian cancer susceptibility (HBC/HBOC) genes, BRCA1, BRCA2 and PALB2, have been shown to recur in French Canadians of Quebec, Canada, and this has been attributed to common ancestors.
|
25925845 |
2015 |